Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Jacobio Pharmaceuticals China

Website:
www.jacobiopharma.com
Company Size (Fulltime employees)
51-200
Year of foundation
5
Biotech/Pharma Category
Dr Yinxiang Wang
Chairman and CEO 
Functionality
Management
Ms Luyao Wang
Director of PR 
Functionality
Other

janssen China

Xi 'an Janssen Pharmaceutical Co., Ltd. is the largest pharmaceutical joint venture in China and the largest subsidiary of Johnson & Johnson in China. Founded in 1985, the company is headquartered in Beijing, with its production base located in Xi 'an and over 3,000 employees. The company's business includes the production and sale of high quality pharmaceuticals, mainly in the fields of gastroenterology, neuropsychiatry, allergy, pain management, anti-infection, biological agents and oncology.
Website:
https://www.xian-janssen.com.cn/
Partnering Objectives
Headquartner in China
No
Biotech/Pharma Category
鑫鑫 闵
医学教育经理 

Jemincare China

Jemincare is a leading pharmaceutical group in China with $5.2B revenue in 2019. JeminCare is dedicated to providing novel healthcare solutions with Rx and OTC drugs with strategic fields in renal disease, oncology, cardiovascular, anti-infection, respiratory, and analgesic. We have a well-established marketing and sales network in China with a team of more than 5000 sales reps.

Located in Shanghai, Jemincare R&D center has 400+ experienced scientists and more than 30 novel prescription drugs in the pipeline.

Website:
http://www.jmkx.com/en/
Company Size (Fulltime employees)
5000+
Year of foundation
1999
Partnering Objectives
Please specify your partnering goal
1) Seeking out-licensing opportunities for 6 innovative and differentiated assets (global excluding China); 2) Seeking in-licensing opportunities of late-stage assets (China)
Headquartner in China
Yes
Biotech/Pharma Category
Assets Information 1
JMKX0623 (NaV1.8 blocker)
Assets Information 2
JMKX1657 (selective AR degradation drug)
Assets Information 3
JMKX1899 (KRAS-G12C inhibitor)
Biotech/Pharma Asset Stage
Mrs. Lilian Peng
BD Manager 
Functionality
Business Development

Jiangbei New area China

JIANGBEI NEW AREA IS THE 13rd national new area，and 1st in jiangsu province.
Website:
www.njna.nanjing.gov.cn
Partnering Objectives
Headquartner in China
Yes
Qin Liu
manager 

Jiangsu Carephar Pharmaceutical Co.,Ltd China

Jiangsu Carephar Pharmaceutical Co.,Ltd
Website:
www.carephar.com
Partnering Objectives
Headquartner in China
Yes
yu hui
BD 
Functionality
Business Development

Jiangsu Hengrui Medicine Co.,Ltd. China

Founded in 1970, Jiangsu Hengrui Medicine Co., Ltd. (JHM) is the largest publicly listed and a leading biopharma based in China with 24,700 employees devoted to empowering healthier lives through research. With over $3.3 billion in revenue in 2019, JHM has 6 new molecular entities approved in China as well as 30+ programs in clinical development in China, US, and Australia across oncology, anesthesiology & analgesics, autoimmune, and metabolic & cardiovascular therapeutic areas. Driven by internal R&D and global licensing and collaboration, JHM is committed to bring high quality products to patients.
Website:
http://www.hrs.com.cn/company_summary.html
Company Size (Fulltime employees)
5000+
Year of foundation
50 years
Partnering Objectives
Please specify your partnering goal
In-licensing clinical stage assets for China market; out-licensing ex-China rights of Hengrui assets
Headquartner in China
Yes
Biotech/Pharma Category
Assets Information 1
Please see the link below for our pipeline. Most of our assets are out-licensing candidates|https://www.hengruius.com/pipeline.html||China, US and global (please check with us for detailed info)
Ms. Linda Zhao
Head, US BD Team 
Functionality
Business Development

Jiangsu Hengrui Pharma China

Hengrui is the largest pharmaceutical company based in China by market cap (around 90 billion USD) and among the top ones by revenue and R&D spending (3.28b USD and 549m USD in 2019, respectively). 5+ differentiated products in global clinical development with commercial rights available for discussions.
Website:
http://www.hrs.com.cn/
Company Size (Fulltime employees)
5000+
Partnering Objectives
Please specify your partnering goal
Looking for Assets to in license and global partners
Headquartner in China
Yes
Biotech/Pharma Category
Assets Information 1
SHR-1701|SHR-1701is an anti-PD-L1/TGF-βRII bi-functional fusion protein that inhibits PD-L1 andTGF-β. It is currently under phase II and phase I clinical development in China and Australia, respectively. Preliminary data from SHR-1701’s two phase I trials showed promising efficacy and safety.|Solid tumor|
Assets Information 2
Pyrotinib|Pyrotinib is a novel selective tyrosine kinase inhibitor of EGFR/HER2/HER4, with superior efficacy vs. lapatinib. Global registrational trial ongoing; approved in China.|HER2-positive breast cancer|
Assets Information 3
Fluzoparib|Fluzoparib is a PARP inhibitor to address ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, and other advanced solid tumors.|Solid tumor|
Biotech/Pharma Asset Stage
Dr. Duan Wang
Associate Director of BD 
Functionality
Business Development

Jiangxi Jemincare Group Co., Ltd. China

One Top Chinese Pharma

Website:
www.jemincare.com/en/
Partnering Objectives
Headquartner in China
Yes
Ben Yang
Business Development Manager 

Jianlian Group China

Jianmin Group is a integrated pharmaceutical company with a major focus on pediatric product development manufacturing, and marketing.
Website:
www.whjm.com
Partnering Objectives
Headquartner in China
Yes
平 郭
BD 

Jianmin Pharma Group China

Jianmin Group (600976.SSE) is an integrated pharmaceutical company with a major focus on pediatric product development, manufacture, and marketing. Founded in 1953, headquartered in Wuhan, the largest city in Central China, its history can be traced back to 17th century. Jianmin has been a famous pharma brand in China among children and their parents for generations. Its rich pediatric portfolio ranges from nutrition, hematology, respiratory, digestive, CNS, to infections and common cold as well.

Website:
www.whjm.com
Company Size (Fulltime employees)
1001-5000
Partnering Objectives
Headquartner in China
Yes
Mr Wei Li
Head of Business Development